Palatin Technologies (PTNT) Stock Price, News & Analysis

Company Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Key Stats

• Today's Range: $25.58 to $25.59
• 50-Day Range: $5.60 to $25.59
• 52-Week Range: $1.75 to $72.50
• Volume: 49,212 shs
• Average Volume: 23,171 shs
• Market Capitalization: $24.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PTNT Stock Analysis - Frequently Asked Questions

How have PTNT shares performed this year?

Palatin Technologies' stock was trading at $5.60 at the beginning of the year. Since then, PTNT stock has increased by 357.0% and is now trading at $25.5930.

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (OTCMKTS:PTNT) released its quarterly earnings data on Wednesday, May, 15th. The biopharmaceutical company reported ($26.50) earnings per share for the quarter, missing analysts' consensus estimates of ($25.00) by $1.50.
Read the conference call transcript.

When did Palatin Technologies' stock split?

Palatin Technologies's stock reverse split on the morning of Tuesday, August 12th 2025.The 1-50 reverse split was announced on Tuesday, August 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Palatin Technologies?

Shares of PTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/15/2024
• Today: 5/07/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:PTNT
• Previous Symbol: PINK:PTNT
• CIK: 911216
• Web: www.palatin.com
• Phone: (609) 495-2200
• Fax: 609-495-2202
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($60.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29.74 million
• Net Margins: N/A
• Pretax Margin: -1,590.66%
• Return on Equity: N/A
• Return on Assets: -365.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.38
• Quick Ratio: 0.38

Sales & Book Value

• Annual Sales: $4.49 million
• Price / Sales: 5.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.25) per share
• Price / Book: -102.37

Miscellaneous

• Outstanding Shares: 973,000
• Free Float: 18,160,000
• Market Cap: $24.90 million
• Optionable: Not Optionable
• Beta: 0.75